Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-1 in cultured cardiac fibroblasts

European Journal of Heart Failure

Volumn 12, Issue 3, 2010, Pages 219-226

  Shyu, Kou Gi ^a,b   Wang, Bao Wei ^a,c   Chen, Wei Jan ^d   Kuan, Peiliang ^a   Hung, Chi Ren ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Endoglin; Fibroblast; Fibrosis; Statin; Transforming growth factor 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ATORVASTATIN; COLLAGEN TYPE 1; ENDOGLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RNA; SMAD3 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; WORTMANNIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST CULTURE; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANIMALS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; COLLAGEN TYPE I; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77249121584     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq011     Document Type: Article

References (32)

1. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation 2000;101:2981-2988.
2. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-b1. Mol Genet Metabol 2000;71:418-435.
3. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-b function blocking prevents myocardial fibrosis and dias-tolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
4. Lim H, Zhu YZ. Role of transforming growth factor-b in the progression of heart failure. Cell Mol Life Sci 2006;63:2584-2596.
5. Fonsatti E, Altomonte M, Arslan P, Maio M. Endoglin (CD105): a target for anti-angiogenic cancer therapy. Curr Drug Targets 2003;4:291-296.
6. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor-b receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004;95:1167-1173.
7. Rodŕiguez-Barbero A, Obreo J, Alvarez-Munoz P, Pandiella A, Bernabéu C, López-Novoa JM. Endoglin modulation of TGF-b1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem 2006;18:135-142.
8. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-I expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006;291:H1378-H1345.
9. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006;98:730-742.
10. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-b stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 2006;70:1992-2003.
11. Horwich TB, MacLellan R, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-648.
12. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalization for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 2007;115:576-583.
13. Pospisilova N, Semeeky V, Jamborova G, Pospechova K, Solichova D, Abdrys C, Zdansky P, Nachtigal P. Endoglin expression in hypercholesterolemia and after atorvastatin treatment in apo-E deficient mice. J Pharm Pharma Sci 2006;9:388-397.
14. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Semecky V. Endothelial expression of endoglin in normocholesterole-mic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol 2007;85:767-773.
15. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implication for ventricular remodeling. Clin Exp Pharmacol Physiol 2005;32:697-701.
16. Gustafsson AB, Brunton LL. b-Adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1b via message stabilization. Mol Pharmacol 2000;58:1470-1478.
17. Shyu KG, Wang BW, Yang YH, Tsai SC, Lin S, Lee CC. Amphetamine activates connexin43 gene expression in cultured neonatal rat cardiomyocytes through JNK and AP-1 pathway. Cardiovasc Res 2004;63:98-108.
18. Shyu KG, Chao YM, Wang BW, Kuan P. Regulation of discoidin domain receptor 2 by cyclic mechanical stretch in cultured rat vascular smooth muscle cells. Hypertension 2005;46:614-621.
19. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P. Carvedilol modulates the expression of hypoxia-inducible factor-1a and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail 2005;11:156-165.
20. Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev 2006;14:108-124.
21. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvasstatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocar-dial infarction. Circulation 2002;105:868-873. (Pubitemid 34174929)
22. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139-148.
23. Laufs U, La FV, Plutzky LJK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
24. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H. Amelioration of angiotensin II-induced cardiac injury by a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Circulation 2001;104:576-581. (Pubitemid 32738128)
25. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavas-tatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signaling pathway. Clin Exp Pharmacol Physiol 2006;33:1164-1171.
26. Patel R, Naguch SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simavastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
27. Porter KE, Turner NA, O'Regan DJ, Balmforth AJ, Ball SG. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004;61:745-755.
28. Zhai Y, Gao X, Wu Q, Peng L, Lin J, Zuo Z. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-b1/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 2008;587:196-203.
29. Yagi S, Aihara KI, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II-induced cardiovascular remodeling and renal insufficiency. Circ Res 2008;102:68-76.
30. Garcia-Pozo L, Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Monzon C. Endoglin: structure, biological functions and role in fibrogenesis. Rev Esp Enferm Dig 2008;100:355-360.
31. Rodriguez-Pena A, Eleno N, Duwell A, Arevalo M, Perez-Barriocanal F, Flores O, Docherty N, Bernabeu C, Letarte M, Lopez-Novoa JM. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002;40: 713-720.
32. Evans RA, Tian YC, Steadman R, Philips AO. TGF-b1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003;282:90-100.